SubventionNational Institutes of Health

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

À propos de cet appel

National Institutes of Health · Instrument: cooperative_agreement · Category: health

Origine

Ces informations proviennent de grants.gov. Vérifiez-y l’éligibilité et la date limite avant de candidater.

Source: Grants.gov. This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.